Table 2.
Expression of Cx43 CT domain in osteocytes does not alter the effects of intermittent PTH administration in cancellous bone
| FEMUR | |||||
|---|---|---|---|---|---|
| Cx43fl/fl | Cx43ΔCT/fl | Cx43fl/fl; DMP1- 8kb-Cre | Cx43ΔCT/fl; DMP1-8kb-Cre | ||
| BV/TV (percent) | vehicle | 10.50 ± 3.42 | 5.84 ± 1.29* | 11.71 ± 3.80 | 5.22 ± 2.39§ |
| PTH | 17.23 ± 6.61# | 9.53 ± 3.14# | 26.67 ± 12.82# | 9.08 ± 4.91# | |
| VERTEBRA | |||||
| Cx43fl/fl | Cx43ΔCT/fl | Cx43fl/fl; DMP1- 8kb-Cre | Cx43ΔCT/fl; DMP1-8kb-Cre | ||
| BV/TV (percent) | vehicle | 23.23 ± 3.02 | 18.06 ± 3.86* | 24.35 ± 4.73 | 19.90 ± 2.25§ |
| PTH | 29.98 ± 3.45# | 24.20 ± 4.13# | 31.99 ± 5.39# | 25.02 ± 1.97# | |
| ObS/BS (percent) | vehicle | 16.27 ± 3.80 | 10.13 ± 2.63* | 17.04 ± 5.40 | 10.30 ± 1.48§ |
| PTH | 26.31 ± 0.92# | 22.43 ± 5.45# | 25.08 ± 3.26# | 20.65 ± 2.17# | |
| NOb/Tar (/mm) | vehicle | 159.09 ± 26.90 | 80.37 ± 13.31* | 169.54 ± 51.85 | 102.16 ± 19.34§ |
| PTH | 260.07 ± 69.64# | 215.13 ± 43.93# | 312.41 ± 65.91# | 218.81 ± 12.98# | |
| NOb/BPm (/mm) | vehicle | 15.64 ± 3.00 | 9.34 ± 1.9*4 | 16.53 ± 4.90 | 10.07 ± 1.30§ |
| PTH | 24.73 ± 3.25# | 22.30 ± 4.11# | 24.67 ± 2.62# | 21.23 ± 1.13# | |
| MAR (μm/day) | vehicle | 1.64 ± 0.19 | 1.37 ± 0.27 | 1.54 ± 0.15 | 1.60 ± 0.32 |
| PTH | 1.61 ± 0.15 | 2.02 ± 0.70 | 1.71 ± 0.20 | 1.80 ± 0.18 | |
| MS/BS (percent) | vehicle | 61.66 ± 2.57 | 44.15 ± 16.78* | 65.23 ± 4.87 | 45.64 ± 20.18§ |
| PTH | 67.10 ± 4.19# | 64.92 ± 11.23# | 72.30 ± 0.65# | 65.42 ± 5.36# | |
| BFR/BS (μm3/μm2/day) | vehicle | 0.97 ± 0.10 | 0.62 ± 0.30* | 1.00 ± 0.09 | 0.69 ± 0.30§ |
| PTH | 1.08 ± 0.07# | 1.26 ± 0.26# | 1.17 ± 0.13# | 1.17 ± 0.11# | |
n=3–11.
*
p<0.05 versus Cx43fl/fl,
§
p<0.05 versus Cx43fl/fl;DMP1-8kb-Cre and
#
p<0.05 versus vehicle-treated mice of the same genotype, by two-way ANOVA.